Planning around chikungunya risk
Trips to India, Brazil, the Caribbean or parts of South East Asia can now raise a very practical vaccine question. Chikungunya is spread by daytime-biting mosquitoes, and outbreaks move around. Northamptonshire Clinic can assess your itinerary, length of stay, age and medical history, then advise whether chikungunya vaccination belongs on your travel plan. This page explains what the infection does, who may be offered the vaccine, and when to book.
A mosquito-borne virus that can leave joints aching for months
Chikungunya is a viral infection passed on mainly by Aedes mosquitoes, particularly Aedes aegypti and Aedes albopictus. These mosquitoes bite during the day, with busy periods often around mid-morning and from late afternoon towards twilight. They breed close to people, including in small containers of standing water around homes, hotels and urban neighbourhoods.
Symptoms usually start about four to eight days after an infected bite, although this can vary. Fever often comes on quickly. Joint pain can be the standout symptom, especially in the wrists, hands, ankles and other smaller joints. Headache, muscle aches, rash and sensitivity to light can also occur.
Most people recover within one or two weeks. The problem is the tail. Joint pain can persist for months, and occasionally longer, which is not ideal if you are returning to work, caring for children, or already have joint problems. Severe complications are uncommon, but risk is higher in young babies, older adults and people with underlying medical conditions.
What the chikungunya vaccine can and cannot do
Chikungunya vaccines are now approved for use in the UK, but they are not a blanket recommendation for every tropical trip. Current UK advice says vaccination may be considered for travellers going to regions with active chikungunya outbreaks, long-term or frequent travellers to places where transmission has occurred in recent years, and laboratory staff working with the virus.
The vaccines are given as a single injection into a muscle, usually the upper arm. Current guidance includes a non-replicating virus-like particle vaccine that may be used from age 12, and a live attenuated vaccine for immunocompetent adults aged 18 to 59. The live vaccine is currently not advised for older adults, and it is not suitable for some people with immune system problems or a history of thymus disorder. This is exactly why a proper pre-travel assessment matters.
Book as early as you can once your route is clear. The need for revaccination has not yet been established. Side effects can include a sore arm, headache, fever, tiredness and muscle or joint aches. Vaccination can reduce risk, but it does not replace mosquito bite avoidance.
Places where chikungunya comes into the conversation
Chikungunya occurs in tropical and subtropical parts of the world, and outbreaks can appear in places that have had little recent activity. Risk has been reported across parts of Asia and Africa, the Indian Ocean islands, the Pacific islands, the Caribbean, Central America and South America. Recent UK travel-associated cases have most often involved travel to India, with cases also linked to Pakistan and Brazil.
Season matters. Outbreaks in tropical countries often increase during or after rainy periods, when mosquito numbers rise. Urban stays are not automatically low risk, because Aedes mosquitoes live very close to people and often bite around houses and accommodation. Before vaccination, your clinician should check current country advice as well as your actual route, accommodation and length of stay.
